查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1883041

肺炎链球菌疫苗市场规模、占有率、成长及全球产业分析：按类型、应用和地区划分的洞察与预测（2024-2032 年）

Pneumococcal Vaccines Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2024-2032
出版日期: | 出版商: Fortune Business Insights Pvt. Ltd. | 英文 159 Pages | 商品交期: 请询问到货日

价格

肺炎链球菌疫苗市场成长驱动因子

由于疾病负担加重、疫苗接种意识提高以及对下一代结合疫苗的投资不断增加，全球肺炎球菌疫苗市场持续稳定成长。根据最近的一份报告，在广泛的免疫接种计划以及儿童和成人强劲需求的推动下，该市场在 2024 年将达到 85 亿美元。随着各国持续加强常规免疫接种覆盖率并加速新型肺炎链球菌结合疫苗 (PCV) 的推广应用，预计到 2025 年，市场规模将扩大至 88 亿美元。在高密度 PCV 创新、政府疫苗接种强制令扩大以及新兴市场需求成长的推动下，预计到 2032 年，全球市场规模将达到 128.7 亿美元。

市场驱动因素

侵袭性肺炎链球菌疾病 (IPD) 发生率的上升仍然是全球肺炎链球菌疫苗接种推广的主要驱动因素。由于慢性疾病、免疫系统减弱和全球人口老化，菌血症、脑膜炎和重症肺炎等传染病的发生率正在上升。例如，在欧盟，欧洲疾病预防控制中心 (ECDC) 报告称，2022 年确诊的侵袭性肺炎球菌病 (IPD) 病例为 17,700 例，表明该疾病持续造成严重的健康负担，并需要扩大血清型覆盖范围。因此，各国政府、公共卫生机构和组织正大力将疫苗接种作为经济有效的预防策略。

国家免疫规划的扩展进一步推动了市场成长。印度于 2021 年在全国推广肺炎链球菌结合疫苗 (PCV)，每年确保超过 6,000 万剂疫苗的供应，覆盖超过 90% 的新生儿。这是全球规模最大的 PCV 推广计画之一。

市场限制因子

儘管需求强劲，但由于肺炎链球菌结合疫苗生产流程复杂，市场仍面临挑战。结合技术（将细菌多醣连接到载体蛋白的过程）需要精密的设备、多道纯化步骤和先进的技术专长。此外，肺炎链球菌疫苗血清型的多样性使得疫苗需要更高的价数，这进一步增加了生产的复杂性。同时，低收入地区缺乏冷藏配送基础设施也导致疫苗降解。根据世界贸易组织 (WTO) 统计，全球 25% 的液体疫苗因冷藏配送中断而降解，凸显了疫苗供应面临的物流障碍。

市场机会

下一代高密度肺炎链球菌结合疫苗 (PCV) 旨在涵盖现有疫苗未涵盖的血清型，代表着巨大的成长机会。赛诺菲、默克、辉瑞和 SK 生物科学等公司正在大力投资研发高密度候选疫苗。 2024年12月，赛诺菲启动了PCV21的全球3期临床试验，辉瑞则持续扩大PCV20的全球推广。这些新一代疫苗有望显着提升全球疾病预防能力，尤其是在高风险成年人群中。

市场趋势

影响行业的一个显着趋势是，人们越来越关注成人肺炎球菌疫苗接种计划。鑑于50岁及以上人口的死亡风险显着更高，各卫生组织已更新其建议，以确保更早接种疫苗。 2024年10月，美国疾病管制与预防中心（CDC）免疫实践咨询委员会（ACIP）扩大了其指导范围，建议所有50岁及以上未接种疫苗的成年人接种PCV疫苗，这推动了美国成人疫苗接种覆盖率的提高，并影响了全球政策的调整。

市场区隔分析

依产品类型

PCV20疫苗凭藉其广泛的血清型覆盖范围和不断扩大的全球获批，占据了市场领先地位。 2024年12月，辉瑞的PCV20疫苗获得香港卫生署批准，进一步扩大了其全球覆盖范围。同时，PPSV23疫苗在成人加强免疫计画中仍然至关重要，与第一剂PCV疫苗联合使用可提供广泛的血清型保护。

依年龄组

由于5岁以下儿童感染风险较高，儿科市场将在2024年占据主导地位。随着雅培公司推出适用于6週及以上婴儿的PneumoShield 14等新产品，早期疫苗接种正在加强。预计成人市场将透过宣传活动和合作稳步成长，例如辉瑞公司和美国肺臟协会共同努力，在2025年推广更新后的成人疫苗接种指南。

依通路划分

政府供应部门凭藉批量采购计划以及与联合国儿童基金会和全球疫苗免疫联盟等国际组织的合作，占据领先地位。医院和零售药局由于疫苗接种管道的改善和免疫接种服务的扩展，正在获得发展动力。

区域展望

北美

北美市场规模预计在2024年达到47.9亿美元，位居榜首。这得益于较高的公众意识、完善的医疗保健基础设施以及积极的研发活动（包括iiCON在2024年提供的350万美元疫苗研发资助）。

欧洲

欧洲市场规模持续维持第二位，主要得益于监理核准的快速推进。 2025年3月，默克公司的CAPVAXIVE（PCV21）获得欧盟委员会批准，可用于成人。

亚太地区

预计到2032年，该地区将实现最快成长，这主要得益于疫苗接种管道的扩大以及印度、中国和日本等国家自主研发的肺炎球菌结合疫苗（PCV）技术。

目录

第一章：引言

第二章：摘要整理

第三章：市场动态

  • 市场驱动因素
  • 市场限制因素
  • 市场机遇
  • 市场趋势

第四章：关键洞察

  • 主要国家和地区的监管环境
  • 主要国家和地区的疫苗接种覆盖率
  • 主要国家和地区的肺炎球菌疫苗政府免疫计划
  • 小儿麻痹疫苗市场的技术进步
  • 主要产业趋势（併购、合作、新产品发表）等等）

第五章：全球肺炎链球菌疫苗市场分析、洞察与预测（2019-2032）

  • 市场分析、洞察与预测 - 按产品类型划分
    • PCV13
    • PCV15
    • PCV20
    • PCV21
    • PPSV23
    • 其他
  • 市场分析、洞察与预测 - 按年龄组别划分
    • 儿童
    • 成人
  • 市场分析、洞察与预测 - 按销售管道划分
    • 医院和零售药局
    • 政府供应商
    • 其他
  • 市场分析、洞察与预测 - 按地区划分
    • 北部美洲
    • 欧洲
    • 亚太地区
    • 拉丁美洲
    • 中东和非洲

第六章 北美肺炎链球菌疫苗市场分析、洞察与预测（2019-2032）

  • 依国家划分
    • 美国
    • 加拿大

第七章：欧洲肺炎链球菌疫苗市场分析、洞察与预测（2019-2032）

  • 依国家划分
    • 德国
    • 英国
    • 法国
    • 义大利
    • 西班牙
    • 斯堪的纳维亚半岛
    • 欧洲其他地区

第八章 亚太地区肺炎链球菌疫苗市场分析、洞察与预测（2019-2032）

  • 依国家划分
    • 中国
    • 日本
    • 印度
    • 澳大利亚
    • 东南亚
    • 亚太其他地区

第九章：拉丁美洲肺炎链球菌疫苗市场分析、洞察与预测（2019-2032）

  • 依国家划分
    • 巴西
    • 墨西哥
    • 拉丁美洲其他地区

第十章：中东与非洲肺炎链球菌疫苗市场分析、洞察与预测（2019-2032）

  • 依国家/地区
    • 海湾合作委员会 (GCC)
    • 南非
    • 中东和非洲其他地区

第十一章 竞争分析

  • 全球市占率分析 (2024)
  • 公司简介
    • 葛兰素史克 (GSK plc.)
    • 默克公司 (Merck & Co., Inc.)
    • 雅培 (Abbott)
    • 赛诺菲 (Sanofi)
    • 辉瑞 (Pfizer)
    • Inventprise
    • Vaxcyte
    • 华生生物技术有限公司 (Walvax Biotechnology Co., Ltd.)
    • SK Bioscience
Product Code: FBI113672

Growth Factors of pneumococcal vaccines Market

The global pneumococcal vaccines market continues to expand steadily due to rising disease burden, growing awareness of preventive vaccination, and increased investment in next-generation conjugate vaccines. According to the latest report, the market size reached USD 8.50 billion in 2024, supported by widespread immunization programs and strong demand from pediatric and adult populations. The market is projected to rise to USD 8.80 billion in 2025 as countries continue to strengthen routine vaccination coverage and accelerate the introduction of new pneumococcal conjugate vaccines (PCVs). By 2032, the global market value is expected to reach USD 12.87 billion, driven by innovation in high-valent PCVs, broader government vaccination mandates, and expansion in emerging economies.

Market Drivers

Rising incidence of Invasive Pneumococcal Disease (IPD) remains the key factor driving pneumococcal vaccine uptake worldwide. These infections-such as bacteremia, meningitis, and severe pneumonia-have seen increasing prevalence due to chronic health conditions, weakened immunity, and ageing global populations. In the European Union, for example, the ECDC reported 17,700 confirmed IPD cases in 2022, illustrating the persistent health burden and need for broader serotype coverage. As a result, governments, public health agencies, and organizations are strongly prioritizing vaccination as a cost-effective preventive strategy.

The expansion of national immunization programs further supports market growth. India's nationwide rollout of the Pneumococcal Conjugate Vaccine (PCV) in 2021 ensured access to over 60 million doses, covering more than 90% of newborns annually-one of the largest PCV introductions globally.

Market Restraints

Despite strong demand, the market faces challenges due to the complex manufacturing process required to produce pneumococcal conjugate vaccines. Conjugation technology-linking bacterial polysaccharides to carrier proteins-requires sophisticated equipment, multiple purification steps, and high technical expertise. Additionally, the vast diversity of pneumococcal serotypes necessitates vaccines with increasing valency, making production even more complicated. Meanwhile, limited cold-chain infrastructure in low-income regions contributes to vaccine spoilage. According to the International Trade Organization, 25% of liquid vaccines worldwide spoil due to broken cold chains, highlighting logistical barriers to broad vaccine deployment.

Market Opportunities

Next-generation high-valent PCVs represent major growth opportunities, aimed at addressing serotypes not covered by existing vaccines. Companies such as Sanofi, Merck, Pfizer, and SK Bioscience are investing heavily in larger-valency pipeline candidates. In December 2024, Sanofi initiated a global phase 3 program for its PCV21, while Pfizer continues expanding its PCV20 reach globally. These next-gen vaccines could significantly enhance global disease protection, especially in high-risk adult populations.

Market Trends

A notable trend shaping the industry is the growing emphasis on adult pneumococcal vaccination programs. With mortality risk significantly higher among individuals aged 50+, health agencies have updated recommendations to ensure earlier vaccination. In October 2024, the CDC's ACIP expanded its guidance to recommend PCV for all PCV-naive adults aged 50 years and older, strengthening adult vaccination uptake in the U.S. and influencing global policy alignment.

Segmentation Analysis

By Product Type

The PCV20 segment holds the leading share due to its broad serotype coverage and growing global approvals. In December 2024, Pfizer's PCV20 received approval from Hong Kong's Department of Health, expanding its global footprint. Meanwhile, PPSV23 remains essential for adult booster programs, offering wide serotype protection when combined with PCV priming doses.

By Age Group

The pediatric segment dominates in 2024 due to the high vulnerability of children under five. New launches like Abbott's PneumoShield 14 for infants over six weeks are strengthening early-age immunization. The adult segment is set for steady expansion through awareness campaigns and partnerships, such as the 2025 Pfizer-American Lung Association initiative promoting updated adult vaccination guidelines.

By Distribution Channel

The government suppliers segment leads due to bulk procurement programs and partnerships with global bodies like UNICEF and Gavi. Hospital and retail pharmacies are gaining traction with improved access and expanded vaccination services.

Regional Outlook

North America

North America led with USD 4.79 billion in 2024, supported by high awareness, robust healthcare infrastructure, and active R&D, including iiCON's USD 3.5 million vaccine development grant in 2024.

Europe

Europe remains the second-largest market, driven by rapid regulatory approvals. In March 2025, Merck's CAPVAXIVE (PCV21) received European Commission approval for adults.

Asia Pacific

Expected to grow fastest through 2032 as nations like India, China, and Japan expand vaccine access and develop indigenous PCV technologies.

Conclusion

With global market value rising from USD 8.50 billion in 2024 to a projected USD 12.87 billion in 2032, the pneumococcal vaccines market is set for robust long-term growth. Strong government immunization programs, increasing disease prevalence, and rapid advancement in next-generation conjugate vaccines will continue shaping the market's upward trajectory throughout the forecast window.

Segmentation

By Product Type

  • PCV13
  • PCV15
  • PCV20
  • PCV21
  • PPSV23
  • Others

By Age Group

  • Pediatric
  • Adults

By Distribution Channel

  • Hospital & Retail Pharmacies
  • Government Suppliers
  • Others

By Region

  • North America (By Product Type, Age Group, Distribution Channel, and Country)
    • U.S.
    • Canada
  • Europe (By Product Type, Age Group, Distribution Channel, and Country)
    • Germany
    • U.K.
    • France
    • Italy
    • Spain
    • Scandinavia
    • Rest of Europe
  • Asia Pacific (By Product Type, Age Group, Distribution Channel, and Country /sub-region)
    • China
    • Japan
    • India
    • Australia
    • Southeast Asia
    • Rest of Asia Pacific
  • Latin America (By Product Type, Age Group, Distribution Channel, and Country /sub-region)
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa (By Product Type, Age Group, Distribution Channel, and Country /sub-region)
    • GCC
    • South Africa
    • Rest of the Middle East & Africa

Table of Content

1. Introduction

  • 1.1. Research Scope
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
  • 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Market Trends

4. Key Insights

  • 4.1. Regulatory Scenarios, By Key Countries/Regions
  • 4.2. Vaccination Coverage- By Key Countries/ Regions
  • 4.3. Government Immunization Programs for Pneumococcal Vaccines- By Key Countries/ Regions
  • 4.4. Technological Advancements in Polio Vaccines Market
  • 4.5. Key Industry Developments (Mergers, Acquisitions, Partnerships, Launches, etc.)

5. Global Pneumococcal Vaccines Market Analysis, Insights and Forecast, 2019-2032

  • 5.1. Market Analysis, Insights and Forecast - By Product Type
    • 5.1.1. PCV13
    • 5.1.2. PCV15
    • 5.1.3. PCV20
    • 5.1.4. PCV21
    • 5.1.5. PPSV23
    • 5.1.6. Others
  • 5.2. Market Analysis, Insights and Forecast - By Age Group
    • 5.2.1. Pediatric
    • 5.2.2. Adults
  • 5.3. Market Analysis, Insights and Forecast - By Distribution Channel
    • 5.3.1. Hospital & Retail Pharmacies
    • 5.3.2. Government Suppliers
    • 5.3.3. Others
  • 5.4. Market Analysis, Insights and Forecast - Region
    • 5.4.1. North America
    • 5.4.2. Europe
    • 5.4.3. Asia Pacific
    • 5.4.4. Latin America
    • 5.4.5. Middle East & Africa

6. North America Pneumococcal Vaccines Market Analysis, Insights and Forecast, 2019-2032

  • 6.1. Market Analysis, Insights and Forecast - By Product Type
    • 6.1.1. PCV13
    • 6.1.2. PCV15
    • 6.1.3. PCV20
    • 6.1.4. PCV21
    • 6.1.5. PPSV23
    • 6.1.6. Others
  • 6.2. Market Analysis, Insights and Forecast - By Age Group
    • 6.2.1. Pediatric
    • 6.2.2. Adults
  • 6.3. Market Analysis, Insights and Forecast - By Distribution Channel
    • 6.3.1. Hospital & Retail Pharmacies
    • 6.3.2. Government Suppliers
    • 6.3.3. Others
  • 6.4. Market Analysis, Insights and Forecast - By Country
    • 6.4.1. U.S.
    • 6.4.2. Canada

7. Europe Pneumococcal Vaccines Market Analysis, Insights and Forecast, 2019-2032

  • 7.1. Market Analysis, Insights and Forecast - By Product Type
    • 7.1.1. PCV13
    • 7.1.2. PCV15
    • 7.1.3. PCV20
    • 7.1.4. PCV21
    • 7.1.5. PPSV23
    • 7.1.6. Others
  • 7.2. Market Analysis, Insights and Forecast - By Age Group
    • 7.2.1. Pediatric
    • 7.2.2. Adults
  • 7.3. Market Analysis, Insights and Forecast - By Distribution Channel
    • 7.3.1. Hospital & Retail Pharmacies
    • 7.3.2. Government Suppliers
    • 7.3.3. Others
  • 7.4. Market Analysis, Insights and Forecast - By Country/Sub-Region
    • 7.4.1. Germany
    • 7.4.2. U.K.
    • 7.4.3. France
    • 7.4.4. Italy
    • 7.4.5. Spain
    • 7.4.6. Scandinavia
    • 7.4.7. Rest of Europe

8. Asia Pacific Pneumococcal Vaccines Market Analysis, Insights and Forecast, 2019-2032

  • 8.1. Market Analysis, Insights and Forecast - By Product Type
    • 8.1.1. PCV13
    • 8.1.2. PCV15
    • 8.1.3. PCV20
    • 8.1.4. PCV21
    • 8.1.5. PPSV23
    • 8.1.6. Others
  • 8.2. Market Analysis, Insights and Forecast - By Age Group
    • 8.2.1. Pediatric
    • 8.2.2. Adults
  • 8.3. Market Analysis, Insights and Forecast - By Distribution Channel
    • 8.3.1. Hospital & Retail Pharmacies
    • 8.3.2. Government Suppliers
    • 8.3.3. Others
  • 8.4. Market Analysis, Insights and Forecast - By Country/Sub-Region
    • 8.4.1. China
    • 8.4.2. Japan
    • 8.4.3. India
    • 8.4.4. Australia
    • 8.4.5. Southeast Asia
    • 8.4.6. Rest of Asia Pacific

9. Latin America Pneumococcal Vaccines Market Analysis, Insights and Forecast, 2019-2032

  • 9.1. Market Analysis, Insights and Forecast - By Product Type
    • 9.1.1. PCV13
    • 9.1.2. PCV15
    • 9.1.3. PCV20
    • 9.1.4. PCV21
    • 9.1.5. PPSV23
    • 9.1.6. Others
  • 9.2. Market Analysis, Insights and Forecast - By Age Group
    • 9.2.1. Pediatric
    • 9.2.2. Adults
  • 9.3. Market Analysis, Insights and Forecast - By Distribution Channel
    • 9.3.1. Hospital & Retail Pharmacies
    • 9.3.2. Government Suppliers
    • 9.3.3. Others
  • 9.4. Market Analysis, Insights and Forecast - By Country/Sub-Region
    • 9.4.1. Brazil
    • 9.4.2. Mexico
    • 9.4.3. Rest of Latin America

10. Middle East & Africa Pneumococcal Vaccines Market Analysis, Insights and Forecast, 2019-2032

  • 10.1. Market Analysis, Insights and Forecast - By Product Type
    • 10.1.1. PCV13
    • 10.1.2. PCV15
    • 10.1.3. PCV20
    • 10.1.4. PCV21
    • 10.1.5. PPSV23
    • 10.1.6. Others
  • 10.2. Market Analysis, Insights and Forecast - By Age Group
    • 10.2.1. Pediatric
    • 10.2.2. Adults
  • 10.3. Market Analysis, Insights and Forecast - By Distribution Channel
    • 10.3.1. Hospital & Retail Pharmacies
    • 10.3.2. Government Suppliers
    • 10.3.3. Others
  • 10.4. Market Analysis, Insights and Forecast - By Country/Sub-Region
    • 10.4.1. GCC
    • 10.4.2. South Africa
    • 10.4.3. Rest of Middle East & Africa

11. Competitive Analysis

  • 11.1. Global Market Share Analysis (2024)
  • 11.2. Company Profiles
    • 11.2.1. GSK plc.
      • 11.2.1.1. Overview
      • 11.2.1.2. Products Types
      • 11.2.1.3. SWOT Analysis
      • 11.2.1.4. Recent Developments
      • 11.2.1.5. Strategies
      • 11.2.1.6. Financials (Based on Availability)
    • 11.2.2. Merck & Co., Inc.
      • 11.2.2.1. Overview
      • 11.2.2.2. Products Types
      • 11.2.2.3. SWOT Analysis
      • 11.2.2.4. Recent Developments
      • 11.2.2.5. Strategies
      • 11.2.2.6. Financials (Based on Availability)
    • 11.2.3. Abbott
      • 11.2.3.1. Overview
      • 11.2.3.2. Products Types
      • 11.2.3.3. SWOT Analysis
      • 11.2.3.4. Recent Developments
      • 11.2.3.5. Strategies
      • 11.2.3.6. Financials (Based on Availability)
    • 11.2.4. Sanofi
      • 11.2.4.1. Overview
      • 11.2.4.2. Products Types
      • 11.2.4.3. SWOT Analysis
      • 11.2.4.4. Recent Developments
      • 11.2.4.5. Strategies
      • 11.2.4.6. Financials (Based on Availability)
    • 11.2.5. Pfizer
      • 11.2.5.1. Overview
      • 11.2.5.2. Products Types
      • 11.2.5.3. SWOT Analysis
      • 11.2.5.4. Recent Developments
      • 11.2.5.5. Strategies
      • 11.2.5.6. Financials (Based on Availability)
    • 11.2.6. Inventprise
      • 11.2.6.1. Overview
      • 11.2.6.2. Products Types
      • 11.2.6.3. SWOT Analysis
      • 11.2.6.4. Recent Developments
      • 11.2.6.5. Strategies
      • 11.2.6.6. Financials (Based on Availability)
    • 11.2.7. Vaxcyte
      • 11.2.7.1. Overview
      • 11.2.7.2. Products Types
      • 11.2.7.3. SWOT Analysis
      • 11.2.7.4. Recent Developments
      • 11.2.7.5. Strategies
      • 11.2.7.6. Financials (Based on Availability)
    • 11.2.8. Walvax Biotechnology Co., Ltd.
      • 11.2.8.1. Overview
      • 11.2.8.2. Products Types
      • 11.2.8.3. SWOT Analysis
      • 11.2.8.4. Recent Developments
      • 11.2.8.5. Strategies
      • 11.2.8.6. Financials (Based on Availability)
    • 11.2.9. SK Bioscience
      • 11.2.9.1. Overview
      • 11.2.9.2. Products Types
      • 11.2.9.3. SWOT Analysis
      • 11.2.9.4. Recent Developments
      • 11.2.9.5. Strategies
      • 11.2.9.6. Financials (Based on Availability)

List of Tables

  • Table 1: Global Pneumococcal Vaccines Market Revenue (USD billion) Forecast, by Product Type, 2019-2032
  • Table 2: Global Pneumococcal Vaccines Market Revenue (USD billion) Forecast, by Age Group, 2019-2032
  • Table 3: Global Pneumococcal Vaccines Market Revenue (USD billion) Forecast, by Distribution Channel, 2019-2032
  • Table 4: Global Pneumococcal Vaccines Market Revenue (USD billion) Forecast, by Region, 2019-2032
  • Table 5: North America Pneumococcal Vaccines Market Revenue (USD billion) Forecast, by Product Type, 2019-2032
  • Table 6: North America Pneumococcal Vaccines Market Revenue (USD billion) Forecast, by Age Group, 2019-2032
  • Table 7: North America Pneumococcal Vaccines Market Revenue (USD billion) Forecast, by Distribution Channel, 2019-2032
  • Table 8: North America Pneumococcal Vaccines Market Revenue (USD billion) Forecast, by Country, 2019-2032
  • Table 9: Europe Pneumococcal Vaccines Market Revenue (USD billion) Forecast, by Product Type, 2019-2032
  • Table 10: Europe Pneumococcal Vaccines Market Revenue (USD billion) Forecast, by Age Group, 2019-2032
  • Table 11: Europe Pneumococcal Vaccines Market Revenue (USD billion) Forecast, by Distribution Channel, 2019-2032
  • Table 12: Europe Pneumococcal Vaccines Market Revenue (USD billion) Forecast, by Country/Sub-Region, 2019-2032
  • Table 13: Asia Pacific Pneumococcal Vaccines Market Revenue (USD billion) Forecast, by Product Type, 2019-2032
  • Table 14: Asia Pacific Pneumococcal Vaccines Market Revenue (USD billion) Forecast, by Age Group, 2019-2032
  • Table 15: Asia Pacific Pneumococcal Vaccines Market Revenue (USD billion) Forecast, by Distribution Channel, 2019-2032
  • Table 16: Asia Pacific Pneumococcal Vaccines Market Revenue (USD billion) Forecast, by Country/Sub-Region, 2019-2032
  • Table 17: Latin America Pneumococcal Vaccines Market Revenue (USD billion) Forecast, by Product Type, 2019-2032
  • Table 18: Latin America Pneumococcal Vaccines Market Revenue (USD billion) Forecast, by Age Group, 2019-2032
  • Table 19: Latin America Pneumococcal Vaccines Market Revenue (USD billion) Forecast, by Distribution Channel, 2019-2032
  • Table 20: Latin America Pneumococcal Vaccines Market Revenue (USD billion) Forecast, by Country/Sub-Region, 2019-2032
  • Table 21: Middle East & Africa Pneumococcal Vaccines Market Revenue (USD billion) Forecast, by Product Type, 2019-2032
  • Table 22: Middle East & Africa Pneumococcal Vaccines Market Revenue (USD billion) Forecast, by Age Group, 2019-2032
  • Table 23: Middle East & Africa Pneumococcal Vaccines Market Revenue (USD billion) Forecast, by Distribution Channel, 2019-2032
  • Table 24: Middle East & Africa Pneumococcal Vaccines Market Revenue (USD billion) Forecast, by Country/Sub-Region, 2019-2032

List of Figures

  • Figure 1: Global Pneumococcal Vaccines Market Revenue Breakdown (USD billion, %) by Region, 2024 & 2032
  • Figure 2: Global Pneumococcal Vaccines Market Value Share (%), by Product Type, 2024 & 2032
  • Figure 3: Global Pneumococcal Vaccines Market Value Share (%), by Age Group, 2024 & 2032
  • Figure 4: Global Pneumococcal Vaccines Market Value Share (%), by Distribution Channel, 2024 & 2032
  • Figure 5: Global Pneumococcal Vaccines Market Value Share (%), by Region, 2024 & 2032
  • Figure 6: North America Pneumococcal Vaccines Market Value (USD billion), by Product Type, 2024 & 2032
  • Figure 7: North America Pneumococcal Vaccines Market Value Share (%), by Product Type, 2024
  • Figure 8: North America Pneumococcal Vaccines Market Value (USD billion), by Age Group, 2024 & 2032
  • Figure 9: North America Pneumococcal Vaccines Market Value Share (%), by Age Group, 2024
  • Figure 10: North America Pneumococcal Vaccines Market Value (USD billion), by Distribution Channel, 2024 & 2032
  • Figure 11: North America Pneumococcal Vaccines Market Value Share (%), by Distribution Channel, 2024
  • Figure 12: North America Pneumococcal Vaccines Market Value (USD billion), by Country, 2024 & 2032
  • Figure 13: North America Pneumococcal Vaccines Market Value Share (%), by Country, 2024
  • Figure 14: Europe Pneumococcal Vaccines Market Value (USD billion), by Product Type, 2024 & 2032
  • Figure 15: Europe Pneumococcal Vaccines Market Value Share (%), by Product Type, 2024
  • Figure 16: Europe Pneumococcal Vaccines Market Value (USD billion), by Age Group, 2024 & 2032
  • Figure 17: Europe Pneumococcal Vaccines Market Value Share (%), by Age Group, 2024
  • Figure 18: Europe Pneumococcal Vaccines Market Value (USD billion), by Distribution Channel, 2024 & 2032
  • Figure 19: Europe Pneumococcal Vaccines Market Value Share (%), by Distribution Channel, 2024
  • Figure 20: Europe Pneumococcal Vaccines Market Value (USD billion), by Country/Sub-Region, 2024 & 2032
  • Figure 21: Europe Pneumococcal Vaccines Market Value Share (%), by Country/Sub-Region, 2024
  • Figure 22: Asia Pacific Pneumococcal Vaccines Market Value (USD billion), by Product Type, 2024 & 2032
  • Figure 23: Asia Pacific Pneumococcal Vaccines Market Value Share (%), by Product Type, 2024
  • Figure 24: Asia Pacific Pneumococcal Vaccines Market Value (USD billion), by Age Group, 2024 & 2032
  • Figure 25: Asia Pacific Pneumococcal Vaccines Market Value Share (%), by Age Group, 2024
  • Figure 26: Asia Pacific Pneumococcal Vaccines Market Value (USD billion), by Distribution Channel, 2024 & 2032
  • Figure 27: Asia Pacific Pneumococcal Vaccines Market Value Share (%), by Distribution Channel, 2024
  • Figure 28: Asia Pacific Pneumococcal Vaccines Market Value (USD billion), by Country/Sub-Region, 2024 & 2032
  • Figure 29: Asia Pacific Pneumococcal Vaccines Market Value Share (%), by Country/Sub-Region, 2024
  • Figure 30: Latin America Pneumococcal Vaccines Market Value (USD billion), by Product Type, 2024 & 2032
  • Figure 31: Latin America Pneumococcal Vaccines Market Value Share (%), by Product Type, 2024
  • Figure 32: Latin America Pneumococcal Vaccines Market Value (USD billion), by Age Group, 2024 & 2032
  • Figure 33: Latin America Pneumococcal Vaccines Market Value Share (%), by Age Group, 2024
  • Figure 34: Latin America Pneumococcal Vaccines Market Value (USD billion), by Distribution Channel, 2024 & 2032
  • Figure 35: Latin America Pneumococcal Vaccines Market Value Share (%), by Distribution Channel, 2024
  • Figure 36: Latin America Pneumococcal Vaccines Market Value (USD billion), by Country/Sub-Region, 2024 & 2032
  • Figure 37: Latin America Pneumococcal Vaccines Market Value Share (%), by Country/Sub-Region, 2024
  • Figure 38: Middle East & Africa Pneumococcal Vaccines Market Value (USD billion), by Product Type, 2024 & 2032
  • Figure 39: Middle East & Africa Pneumococcal Vaccines Market Value Share (%), by Product Type, 2024
  • Figure 40: Middle East & Africa Pneumococcal Vaccines Market Value (USD billion), by Age Group, 2024 & 2032
  • Figure 41: Middle East & Africa Pneumococcal Vaccines Market Value Share (%), by Age Group, 2024
  • Figure 42: Middle East & Africa Pneumococcal Vaccines Market Value (USD billion), by Distribution Channel, 2024 & 2032
  • Figure 43: Middle East & Africa Pneumococcal Vaccines Market Value Share (%), by Distribution Channel, 2024
  • Figure 44: Middle East & Africa Pneumococcal Vaccines Market Value (USD billion), by Country/Sub-Region, 2024 & 2032
  • Figure 45: Middle East & Africa Pneumococcal Vaccines Market Value Share (%), by Country/Sub-Region, 2024
  • Figure 46: Global Pneumococcal Vaccines Market Share (%), by Company, 2024